Shanghai Changzheng Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
Pancreatic Cancer and Diabetes Mellitus
Not yet recruiting
- Conditions
- Pancreatic CancerSurgeryDiabetes Mellitus
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06585072
Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy
Completed
- Conditions
- Thyroid-Associated Ophthalmopathy
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06585592
The Risk Factors and Its Prognosis of Hyperglycemia Secondary to Pancreatic Surgery
Completed
- Conditions
- Pancreatic SurgeyDiabetes Mellitus
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 382
- Registration Number
- NCT06585046
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06583993
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Naval Medical University, Shanghai, Shanghai, China
The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Early Phase 1
Not yet recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Genetic: Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06572189
- Locations
- 🇨🇳
Wen-Ping Xu, Shanghai, Shanghai, China
Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Diagnostic Test: Blood draw
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT06509919
- Locations
- 🇨🇳
Changzheng hospital, Shanghai, Shanghai, China
The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06473493
The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT06470386
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06418659
- Locations
- 🇨🇳
Changzheng Hospital, Shanghai, Shanghai, China
UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes
Not Applicable
Recruiting
- Conditions
- Newly Diagnosed Type 1 Diabetes Mellitus
- Interventions
- Drug: UCMSCsDrug: Placebo
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06407297
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath